


Details of the cohort

Patient ID	Age	Sex	Histology	TNM Stage	Chemotherapy regimen
1	69	Female	Large Cell	T3N0M0	C/E
2	75	Male	Large Cell	T2N2M0	C/E
3	77	Male	SCC	T2N2M0	C/P
4	75	Female	Large Cell	T1N1M0	C/P
5	62	Male	SCC	T1N2M0	C/E
6	57	Female	AdenoCA	T1N0M0	C/P
7	84	Male	SCC	T2N0M0	C/P
8	67	Male	SCC	T1N0M0	C/P
9	64	Female	SCC	T4N3M0	C/E
11	60	Male	Large Cell	T2N1M0	C/P
12	47	Female	AdenoCA	T1N3M0	C/E
13	65	Male	Large Cell	T3N3M0	C/E
14	73	Male	AdenoCA	T2N3M0	C/E
15	52	Female	AdenoCA	T2N2M0	C/P
16	56	Male	AdenoCA	T2N3M0	C/P
17	81	Male	SCC	T3N1M0	C/P
18	63	Female	NS	T2N2M0	C/E
19	57	Female	SCC	T2N2M0	C/P
21	74	Male	SCC	T4N0M0	C/P
22	64	Female	AdenoCA	T1N2M0	C/E
23	53	Female	AdenoCA	T4N3M0	C/E
24	63	Female	AdenoCA	T4N3M0	C/E
25	78	Female	SCC	T2N2M0	C/P
26	67	Male	SCC	T1N2M0	C/P
28	80	Male	SCC	T1bN2M0	C/P
29	53	Female	SCC	T1N3M0	C/E
30	61	Male	SCC	T1N0M0	C/P
31	63	Male	AdenoCA	T2N3M0	C/E
32	54	Female	AdenoCA	T3N3M0	C/P
33	59	Male	AdenoCA	T2N2M0	C/P
34	64	Female	SCC	T2N3M0	C/E
35	83	Male	NS	T2N0M0	C/P
36	63	Female	SCC	T2N2M0	C/P
38	56	Female	AdenoCA	T2bN3M0	C/E
39	86	Male	AdenoCA	T2bN2M0	C/P
40	55	Female	AdenoCA	T1N1M0	C/E
41	82	Male	SCC	T2N3M0	C/P
42	67	Male	Neuroendocrine	T1bN2M0	C/E
43	57	Male	AdenoCA	T1N2M0	C/E
44	80	Male	SCC	TxN3M0	C/P
45	66	Male	AdenoCA	T3/4N2M0	C/E
46	67	Female	NS	T2N0M0	C/P
47	62	Male	SCC	T2N2M0	C/P
48	72	Male	Neuroendocrine	T3N1M0	C/P
50	68	Female	AdenoCA	T1bN2M0	C/P
51	70	Male	AdenoCA	T3N2M0	C/P
52	78	Male	AdenoCA	T4N2M0	C/E
53	68	Male	AdenoCA	T2aN3M0	C/E
54	77	Male	AdenoCA	T2bN2M0	C/P
55	31	Female	AdenoCA	T1aN3M1a	C/E
56	69	Male	AdenoCA	T1bN3M0	C/E
57	74	Male	AdenoCA	T3N0M0	C/P
58	68	Male	AdenoCA	T1bN2M0	C/E
59	84	Male	AdenoCA	T1bN1M0	C/P
60	64	Male	AdenoCA	T2aN3M0	C/E
61	80	Male	SCC	T4N0M0	C/P
62	65	Male	SCC	T2N2M0	C/P
63	64	Male	SCC	T1N3M0	C/E
65	68	Female	SCC	T2bN1M0	C/E
67	54	Male	NS	T2N2M0	C/E


Blood counts performed for standard clinical management.

Acute toxicity of C/E regimen (A) compared to C/P (B). Green curves represent the patient with FLT PET/CT SUVmax values closest to median bone marrow values for the C/E and C/P cohorts, as highlighted in Figure 1A-B, respectively 1C-D.



Blood smears illustrating increase of neutrophil counts at Week 2 in support to Figure 3

Prospective blood collection at the time of each FLT PET/CT demonstrate in both chemotherapy regimen that neutrophils did slightly increase at Week 2. Representative C/E and C/P patient 10x magnification pictures of blood smears at the 3 time points (white blood cells have deep blue-purple nuclei) (A). Cell counts per field in these two patients (B). Black lines: median SUVmax values; NS: non significant



Supplemental Figure 3

Analysis of baseline, Week 2 and Week 4 FDG SUVmax uptake in the bone marrow, spleen and liver

Representative C/E patient P14 (A). Compared to FLT (Figures 1 & 2), less intense uptake in the bone marrow and less uptake variation in all organs than FLT are demonstrated (B).

Black lines: median FDG SUV_{max} values; Blue lines: median FLT SUV_{max} values from Figure 1 and 2; ns: non significant; *: p<0.05; **: p<0.01; ***: p<0.001.

